Metagenomi Therapeutics (MGX) Total Current Liabilities (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Total Current Liabilities of $22.5 million for Q1 2026, down 43.6% year-over-year from $39.9 million in Q1 2025, and down 1.89% quarter-over-quarter from $22.9 million in Q4 2025.
Metagenomi Therapeutics (MGX) Total Current Liabilities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Total Current Liabilities for 4 consecutive years, with $22.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 43.6% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $22.5 million (down 43.6% YoY), while the FY2025 annual figure was $22.9 million, down 38.53% from the prior year.
- Total Current Liabilities fell to $22.5 million in Q1 2026 per MGX's latest filing, from $22.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $70.7 million in Q1 2024 and bottomed at $22.5 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $42.4 million across 4 years, with a median of $38.6 million in 2024.
- Annual changes were most pronounced in 2024 — Total Current Liabilities slumped 45.82% — and 2025, when it tumbled 35.26%.
- Metagenomi Therapeutics' Total Current Liabilities stood at $68.9 million in 2023, then plunged by 45.82% to $37.3 million in 2024, then slumped by 38.53% to $22.9 million in 2025, then slipped by 1.89% to $22.5 million in 2026.
- Business Quant data shows MGX's Total Current Liabilities at $22.5 million in Q1 2026, $22.9 million in Q4 2025, and $29.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 27.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.63 Mn |
| Mar 31, 2026 | 22.50 Mn |
| Dec 31, 2025 | 22.93 Mn |
| Sep 30, 2025 | 29.58 Mn |
| Jun 30, 2025 | 33.27 Mn |
| Mar 31, 2025 | 39.89 Mn |
| Dec 31, 2024 | 37.31 Mn |
| Sep 30, 2024 | 45.69 Mn |
| Jun 30, 2024 | 52.81 Mn |
| Mar 31, 2024 | 70.70 Mn |
| Dec 31, 2023 | 68.86 Mn |